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Objective: We have investigated the polygenic architecture of Parkinson disease (PD) and have also explored the
potential relationship between an individual’s polygenic risk score and their disease age at onset.
Methods: This study used genotypic data from 4,294 cases and 10,340 controls obtained from the meta-analysis of
PD genome-wide association studies. Polygenic score analysis was performed as previously described by the Interna-
tional Schizophrenia Consortium, testing whether the polygenic score alleles identified in 1 association study were
significantly enriched in the cases relative to the controls of 3 independent studies. Linear regression was used to
investigate the relationship between an individual’s polygenic score for PD risk alleles and disease age at onset.
Results: Our polygenic score analysis has identified significant evidence for a polygenic component enriched in the
cases of each of 3 independent PD genome-wide association cohorts (minimum p53.76 3 1026). Further analysis
identified compelling evidence that the average polygenic score in patients with an early disease age at onset was
significantly higher than in those with a late age at onset (p50.00014).
Interpretation: This provides strong support for a large polygenic contribution to the overall heritable risk of PD and
also suggests that early onset forms of the illness are not exclusively caused by highly penetrant Mendelian muta-
tions, but can also be contributed to by an accumulation of common polygenic alleles with relatively low effect sizes.
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The identification of rare highly penetrant mutationsin genes causing familial and early onset Parkinson
disease (PD)1–5 has considerably improved our under-
standing of disease pathogenesis. Recently, our under-
standing of idiopathic PD has been enhanced by
genome-wide association (GWA) studies6–16 that have
collectively identified PD risk variants at >18 loci.6,7
Despite their high levels of significance, these 18 loci are
thought to account for only a very small amount (3–5%)
of the expected heritability of PD.17 GWA study data
sets can be used to determine a polygenic contribution of
common single nucleotide polymorphisms (SNPs) that
show disease association but fail to meet the significance
threshold for genome-wide significance (p> 5 3 1028)
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to PD. Recent studies confirm that when weak effect loci
are also considered17 there is a substantial increase in the
estimated heritability detected in PD GWA studies
(24%), and this strongly implies that a large proportion
of genetic signal must lie below the genome-wide signifi-
cance thresholds set in the primary analyses.
Polygenic score analysis tests whether the alleles of
small effect that GWA studies are underpowered to
detect confer an aggregate risk and whether the same sets
of risk alleles are shared between cohorts/data sets.18 We
have investigated the polygenic contribution to PD by
assessing whether score alleles identified in a GWA study
from the United Kingdom are significantly enriched in
cases from 3 independent GWA studies.
The age at onset (AAO) of PD has a relatively high
heritability19 and has been previously shown to be associ-
ated with a small number of common variants,14,20 some
of which are strongly associated with disease.14 Using
polygenic score analysis, we have considered PD accord-
ing to a liability threshold model. Conceptually, liability
is a quantitative measure that represents all risk factors
that determine whether an individual will develop a dis-
ease. The liability threshold model assumes that individu-
als with a total liability greater than or equal to a fixed
threshold will develop the disease. Mendelian forms of
PD are caused by rare highly penetrant mutations at a
single disease locus and are also typically associated with
a young AAO. In line with a liability threshold model, a
rare highly penetrant mutation is likely to contribute to
a large proportion of an individual’s disease liability. We
propose that if an individual’s common risk allele poly-
genic score is related to their disease liability we might
expect patients carrying the highest load of common risk
alleles to develop PD at the youngest ages. Conversely, if
a large proportion of these cases are monogenic in
nature, one might expect an attenuation of any relation-
ship between polygenic score and AAO in the very
young, supporting the notion that early onset PD has a
substantial monogenic component.21–23
Our study provides compelling evidence for a poly-
genic contribution to PD, and that an individual’s poly-
genic score is correlated with age at disease onset.
Importantly, this indicates that a liability threshold model
is relevant to PD pathogenesis and that early onset forms
of the illness are not limited to Mendelian subtypes.
Subjects and Methods
PD GWA Data Set
This study used data obtained from the meta-analysis of 5 PD
GWA studies (5,333 PD cases and 12,298 controls) of which
259,577 SNPs passed study-specific quality controls in all stud-
ies.6 The summary statistics for each marker in the PD data set
were obtained using fixed effect inverse variance weighted meta-
analyses with METAL software (http://www.sph.umich.edu/csg/
abecasis/metal/). The AAO and individual genotypes were avail-
able for a total of 4,111 PD cases. For these patients, AAO was
systematically determined at the time of inclusion by a retro-
spective interview and is defined as the age at which PD was
first diagnosed.
Polygenic Score Analysis
We followed the approach previously described by the Interna-
tional Schizophrenia Consortium.18 Essentially this involved the
selection of a set of SNPs that were in relative linkage equilib-
rium (r2< 0.25) and the generation of additive polygenic risk
scores using SNPs with increasingly liberal probability values in
a GWA study discovery data set, which were then tested for
enrichment within an independent test sample.
In this study, we first investigated whether the polygenic
score that was based on the PD GWA results of 1 data set were
significantly enriched in the cases relative to the controls of
another independent PD GWA study. For this analysis, we used
4 natural subsets of the International Parkinson’s Disease
Genomics Consortium (IPDGC) data where the individual
genotypes of both cases (n5 4,294) and controls (n5 10,340)
were available. After random pruning for linkage disequilibrium
(LD; r2< 0.25), there were 59,770 SNPs available for polygenic
score analyses. We used our most powerful PD case/control
subset as our discovery sample (UK GWA study; 1,705 PD
cases/6,200 controls) to select SNPs associated with PD, for
each identifying its probability value for tests of allelic associa-
tion, the effect size, and the allele that was present in the PD
group more frequently than in the controls. We termed these
the "score" alleles and further categorized them according to
whether they met a predetermined significance threshold of
association (p< 0.01, 0.05, 0.1, up to 0.5). We next used
PLINK v1.07 to calculate the polygenic score for each individ-
ual in each of 3 independent case/control cohorts (USA-1, 876
cases/859 controls; USA-2, 971 cases/937 controls; Germany-1;
742 cases/667 controls) as the average number of score alleles
they possessed, each weighted by their effect size (B-coefficient)
log of odds ratio (OR) from the PD discovery sample. Logistic
regression was then used to test whether the polygenic score
distinguished case/control status in the 3 independent studies
(USA-1, USA-2, and Germany-1).
Age at Onset Analysis
To maximize the quality of the LD pruning, we considered it
worthwhile to use the largest and most powerful PD GWA
study available to us (5,333 cases and 12,298 controls). LD
pruning (using r2> 0.25, a physical distance threshold for
clumping SNPs of 250kb, and p5 1 as the significance thresh-
old for SNPs, which allowed us to capture all SNPs, even if
their association with PD was not significant) identified a set of
104,830 independent SNPs that retained those most signifi-
cantly associated with the disease.
The LD-pruned set of SNPs were subsequently used for
polygenic score analysis in the 4,294 PD patients for whom
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genotype data were available (UK, German, USA-1, and USA-
2 GWA studies). Of these, AAO data were available in 4,111
patients (mean AAO5 60.9 years, standard deviation5 12.6),
for whom we identified the score alleles and calculated their
polygenic score. Polygenic scores were then adjusted for the
country of origin using linear regression, and the residuals were
then normalized by subtracting the mean and dividing by the
standard deviation.
To investigate the relationship between an individual’s poly-
genic score for PD risk alleles and disease AAO, we initially used
linear regression analyses of the entire data set. Because clinical
estimates of the AAO of PD will inevitably have limited precision
in predicting the start of an individual’s underlying biological
pathology, we also used chi-square or, where appropriate, Fisher
exact tests to compare the polygenic score between individuals
with AAO at the extremes ends of the AAO distribution.
Results
Polygenic Risk Score Analysis
In this study, we investigated whether the polygenic score
alleles identified in 1 PD GWA study were significantly
enriched in the cases relative to the controls of independ-
ent PD data sets. Polygenic score analysis revealed signifi-
cant evidence for an overall enrichment of the PD score
alleles identified in the UK GWA discovery sample14 in
the cases of each of 3 independent PD GWA cohorts
from the USA (32) and Germany (Table 1).
In accordance with the pattern seen in studies of
other complex diseases shown to have a polygenic sig-
nal,18,24–26 restricting our analysis to SNPs that met the
lowest association test probability value thresholds (pT)
in the discovery sample (pT< 10
24, pT< 10
23,
pT< 0.01, pT< 0.05) did not identify a systematic signif-
icant inflation in the polygenic scores of the PD cases of
the replication samples (p> 0.05). Rather, our most sig-
nificant evidence was observed when SNPs with pT 0.5
in the UK sample were included where probability values
for a significant inflation in the polygenic scores ranged
between 4.42 3 1024 and 8.22 3 1025 (see Table 1).
For all significant associations the B-coefficients were
positive, indicating that the higher polygenic score in the
UK discovery sample corresponds to the higher score in
each of the 3 independent replication samples and pro-
vides evidence for a polygenic contribution to the devel-
opment of PD.
Polygenic Score and AAO
To investigate a potential relationship between an indi-
vidual’s polygenic score and their AAO, we initially used
linear regression of all 4,111 PD patients. This revealed
nominally significant evidence that AAO was correlated
with polygenic score but only when the analysis was
restricted to SNPs with pT< 0.01 (Table 2). Closer
inspection of the regression analyses revealed that
although falling short of nominal significance the B-
coefficients were negative at all pT cutoffs, indicating that
our data showed a consistent trend of higher polygenic
score corresponding to an earlier AAO of PD.
We recognize that imprecision in the clinical esti-
mates of the AAO of PD could adversely affect the
power of our regression analysis. We therefore next com-
pared the polygenic scores of patients whose AAO was at
the lower 5% (AAO< 40 years, n5 248) with those at
the upper 5% (AAO 80 years, n5 196) of the AAO
distribution. This revealed that patients with an
TABLE 1. Results of Polygenic Score Analysis of PD Score Alleles in 3 Independent PD Target Samples
Selection Threshold
of Score SNPs in UK
Discovery Sample
No. of Significant
SNPs at pT in UK
Discovery Sample
p for Polygenic Score Association
in Each Target Sample
Germany-1 USA-1 USA-2
pT< 0.0001 9 0.822 0.039 0.117
pT< 0.001 64 0.711 0.782 0.014
pT< 0.01 655 0.992 0.064 0.156
pT< 0.05 3,167 0.976 0.067 0.004
pT< 0.1 6,265 0.160 0.009 0.003
pT< 0.2 12,256 2.56 3 10
23 1.9 3 1023 4.1 3 1025
pT< 0.3 18,281 2.52 3 10
24 3.44 3 1024 2.65 3 1025
pT< 0.4 24,169 2.17 3 10
24 1.94 3 1024 3.76 3 1026
pT< 0.5 30,157 8.22 3 10
25 4.42 3 1024 1.83 3 1025
PD5Parkinson disease; pT5significance level probability value thresholds for SNP selection in the discovery sample; SNP5 sin-
gle nucleotide polymorphism.
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AAO< 40 years had a significantly higher polygenic
score (mean5 0.14, standard error [SE]5 0.076) than
those with an AAO 80 years (mean520.05,
SE5 0.059). Looking at the numbers of patients with
higher polygenic score categorized by early versus late
onset, we consistently observed this pattern (OR> 1) at
all pT values and for all polygenic scores cutoffs> 0 (Fig
1). Our most significant result was when we compared
patients with polygenic scores> 1.5 (pT5 0.2,
p5 0.00014), which revealed that 33 (13%) of patients
with a polygenic score> 1.5 had an AAO< 40 years,
whereas only 6 (3%) had an AAO 80 years (OR5 4.8,
relative risk [RR]5 4.3). Moreover, our data also
revealed a consistent relationship between disease AAO
and polygenic score at all pT thresholds.
Relaxing our AAO threshold by 65 years at either
end of the AAO distribution demonstrated that although
we consistently observed the same pattern at all thresholds
of AAO, our strongest effects were seen when comparing
the patients at the most extreme ends of the AAO distribu-
tion (Fig 2). It has previously been reported that the
genetic structure in a population can be correlated with
age.27 We investigated the possibility of this adversely
affecting our results by performing an analogous analysis
that compared the distribution of the PD score alleles
between the oldest and youngest 5% (corresponding to
<50 years and >87 years, respectively) of an independent
cohort of Alzheimer disease (AD) patients (3,177 AD cases
and 7,277 controls).28 This failed to identify a significant
difference in the distribution of the PD score alleles
between the 2 age groups (minimum p5 0.49, data not
presented). We therefore conclude that the most likely
explanation for our results being strongest when compar-
ing PD patients at the most extreme ends of the AAO
TABLE 2. Linear Regression Analysis for Association of the Polygenic Score with Age at Onset
pT No. of Significant
SNPs at pT
Effect
(B-coefficient)
p R2
1.00E-04 90 20.48 0.0135 0.0015
0.001 528 20.50 0.0103 0.0016
0.01 3,252 20.43 0.0304 0.0011
0.05 11,757 20.31 0.1172 0.0006
0.1 20,691 20.32 0.1072 0.0006
0.2 35,655 20.32 0.1003 0.0007
0.3 48,448 20.31 0.1163 0.0006
0.4 59,852 20.34 0.0830 0.0007
0.5 69,666 20.33 0.0917 0.0007
pT5significance level probability value thresholds for SNP selection; SNP5 single nucleotide polymorphism.
FIGURE 1: Assessment of the level that polygenic scores>0 are enriched in Parkinson disease patients with age at onset
(AAO)<40 years compared to AAO>80 years. *p<0.05, **p<0.01, ***p<0.001. OR5odds ratio; SD5 standard deviation;
SNP5 single nucleotide polymorphism.
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distribution is a reduction in power due to the inherent
imprecision of relating age at diagnosis to a biological
AAO and also that our selection of PD score alleles inevita-
bly captures a proportion of SNPs that are not causal.
Because the 104,830 independent SNPs that we used
to identify PD score alleles included those most signifi-
cantly associated with the disease, it is plausible that our
results are being artificially biased by SNPs whose evidence
for association is due to or merely a consequence of LD
with the very strong association signal of known GWA
study hits. To investigate this possibility, we repeated our
analysis using identical analysis thresholds but this time
excluding all 1,729 SNPs that after LD pruning were pres-
ent at the 18 genomic regions previously reported to be
strongly associated with PD, including the human leuko-
cyte antigen locus.6 Given that each of these regions is
likely to span at least 1 true PD susceptibility allele that
would now be excluded from our polygenic score analysis,
this approach is highly conservative. Nevertheless, this
analysis again revealed significant evidence that individuals
with higher polygenic scores had on average a lower AAO
of PD, with our most significant result indicating the same
magnitude of RR and OR between polygenic score and
AAO (Fig 3). Moreover, we also obtained analogous results
when we used an alternative method of LD pruning that
ignored the strength to which SNPs were associated with
PD and also excluded SNPs from the 18 associated regions
(data not presented). These analyses suggest that our find-
ings are not dependent on either the previously identified
susceptibility loci or the SNPs that are falsely associated
with PD merely as a consequence of LD with the very
strong association signals.
Discussion
The molecular genetic data reported in this study provides
strong support for a large polygenic contribution to the
overall heritable risk of PD. This implies that the genetic
architecture of PD includes many common variants of
small effect and is likely to be reflected in a large number
of susceptibility genes and a complex set of biological path-
ways relevant to the disease. The PD score alleles identified
in this cohort are not significantly enriched (minimum
p5 0.14) in an independent GWA study for AD,29 indi-
cating that the polygenic component to PD that we have
FIGURE 2: Assessment of the level that polygenic scores>1.5 are enriched in different thresholds of early versus late onset
Parkinson disease patients. *p<0.05, **p<0.01, ***p<0.001. OR5odds ratio; SNP5 single nucleotide polymorphism.
FIGURE 3: Assessment of the level that polygenic scores>1.5 are enriched in different thresholds of early versus late onset
Parkinson disease (PD) patients when 18 regions reported to be associated with PD are excluded. *p<0.05, **p<0.01,
***p<0.001. OR5odds ratio; SNP5 single nucleotide polymorphism.
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identified is disease specific. Moreover, to conduct our
analysis we had to define a training GWA study and a
series of replication data sets. We achieved this by splitting
the IPDGC meta-analysis by its original GWA studies and
observed a similar pattern of results when we defined the
PD score alleles in a sample from the United Kingdom
and tested for enrichment in samples from Germany and
the USA (and vice versa). It is therefore unlikely that our
observations are an artifact of subtle population substruc-
ture present in 1 of our sample cohorts.
We have also investigated the potential relationship
between AAO and polygenic score. To do this we
hypothesized that if a person’s polygenic score represents
a measure of their overall load of PD risk alleles then, in
accordance with a liability threshold model, an individu-
al’s disease liability should be related to their polygenic
score. For established PD risk factors, it is recognized
that rare highly penetrant Mendelian variants (eg, homo-
zygous PARK2 mutations) typically lead to a reduced
AAO when compared to less penetrant disease mutations
(eg, G2019S at LRRK2). As Mendelian mutations are
expected to represent a substantial proportion of a car-
rier’s disease liability, we predicted that PD patients who
do not carry highly penetrant Mendelian risk mutations
but manifest the disease at a younger age would on aver-
age carry the highest polygenic load of common PD sus-
ceptibility alleles. Our study has identified compelling
evidence that supports this hypothesis; patients with an
early AAO consistently had a significantly higher poly-
genic score when compared to those with a late AAO.
This indicates that early onset forms of PD are not lim-
ited to Mendelian genetic subtypes but can also be con-
tributed to by an accumulation of common polygenic
alleles. Moreover, as our study did not include a prescre-
ening to identify highly penetrant mutations, it is possi-
ble that a small number of carriers remain in this cohort;
our analysis can therefore be considered conservative.
As might be expected, we observed our strongest
enrichment when we compared patients with an AAO at
the lower and upper 5% of our sample distribution
(OR5 4.8, RR5 4.3), which suggested that a PD patient
with a polygenic score> 1.5 is 4 times more likely to
develop the disease before the age of 40 years than after 80
years of age. Importantly, by adjusting the polygenic scores
for the country of origin, we minimized any possible
adverse effects of population stratification. Excluding all
SNPs spanning genomic regions that harbor known PD
susceptibility loci did not adversely affect our findings,
implying that the main contribution of the PD polygenic
signal identified in this study is from common SNPs that
show disease association but fail to meet the probability
value threshold for genome-wide significance.
Further studies are required if we are to progress
from evidence for a polygenic contribution to PD to
understanding the specific genetic factors that comprise
the polygenic component. Increasing the discovery sam-
ple size will allow more loci with increasingly small indi-
vidual effect sizes to pass the threshold of genome-wide
significance, and should substantially refine the polygenic
scores derived here. Moreover, as we have previously
shown, using approaches such as gene pathway analyses
it is possible to utilize the polygenic signal captured and
identify genes or biological systems relevant to PD.30
It is possible that our findings are being influenced by
rare PD susceptibility variants that are in LD with the com-
mon alleles analyzed in this study. The ongoing efforts of
studies performing exome and whole genome sequencing in
large numbers of PD case/control cohorts will allow us to
establish the haplotype structure of common and rare alleles,
and will allow us to understand which loci are subject to
"synthetic association."31 Moreover, as previously demon-
strated in other complex diseases,32 future polygenic score
analysis of variants identified by exome/genome sequencing is
expected to further inform our understanding of the genetic
underpinnings of PD. Although it is an important measure,
we recognize that clinical estimates of the AAO of PD can
often actually reflect the age at diagnosis and as such will
inevitably have limited precision in predicting the start of an
individual’s underlying biological pathology. Applying poly-
genic score analyses to the results of large sequencing studies
of clinically well-characterized cohorts will help overcome the
inherent imprecision of measuring AAO and applying poly-
genic score analysis to PD score alleles that inevitably include
a proportion of SNPs that are not causal.
Finally, we have used the term PD score allele, as this
approach cannot differentiate the minority of true PD risk
alleles from variants not associated with the disease. As
such, the derived polygenic scores have little value for pre-
dicting an individual’s risk of developing PD. However,
measures of polygenic burden could prove useful in distin-
guishing PD patients whose disease liability is most likely to
carry the largest or smallest genetic component. Identifying
these individuals would benefit genetic recall studies and
could facilitate a better understanding of how gene–gene
and gene–environment interactions increase risk to PD.
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